Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
9th Jun 20267:00 amRNS-RNew contract trials: Sim Trava and DW Baking
5th Jun 202612:26 pmRNSHolding(s) in Company
5th May 20267:00 amRNSYear End Trading Update
24th Apr 20267:00 amRNSAIM Director Disclosure Update
2nd Apr 20267:00 amRNS-RNew Contract Wins
9th Mar 202610:00 amRNSConcert Party Update
26th Feb 20267:00 amRNSNon-Executive Director Appointments
18th Feb 20267:00 amRNS-RRenewal of Contract
23rd Jan 20267:00 amRNSChange of Non-Executive Director
29th Dec 20259:21 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSCustomer Contracts Update
4th Dec 20255:43 pmRNSHolding(s) in Company
27th Nov 20257:00 amRNSDirector/PDMR Shareholding - Grant of Options
19th Nov 20257:00 amRNSInterim Results
10th Nov 20253:14 pmRNSContract Renewal with Major Global Retailer
3rd Nov 20254:20 pmRNSHolding(s) in Company
31st Oct 20252:46 pmRNSResult of AGM
31st Oct 20259:28 amRNSHolding(s) in Company
31st Oct 20257:00 amRNSHolding(s) in Company
31st Oct 20257:00 amRNSAGM Statement
27th Oct 20254:45 pmRNSHolding(s) in Company
27th Oct 20254:43 pmRNSHolding(s) in Company
6th Oct 20257:00 amRNSAudited Full Year Results
29th Sep 20257:00 amRNSUpdate on Audited Results
22nd Jul 20257:00 amRNSAppointment of Chief Executive Officer
14th Jul 20252:40 pmRNSHolding(s) in Company
7th Jul 20257:00 amRNSContract Renewal with Major UK Wholesaler
4th Jul 20257:00 amRNSAppointment of Finance Director
12th Jun 202510:46 amRNSHolding(s) in Company
5th Jun 20257:00 amRNSAppointment of Chair, Nominated Adviser and Broker
30th May 20257:00 amRNSSecond Interim Results
29th May 20257:00 amRNSContract Renewal with Major British Supermarket
6th May 20257:00 amRNSChange of Accounting Reference Date
15th Apr 20253:58 pmRNSBoard Appointment
26th Mar 202511:00 amRNSBoard Changes
20th Mar 20252:29 pmRNSBoard Change
20th Mar 202512:36 pmRNSForm 8.5 (EPT/RI) - Amendment
20th Mar 202510:25 amRNSForm 8.5 (EPT/RI)
19th Mar 202511:50 amRNSResults of Court Meeting and General Meeting
18th Mar 20259:35 amRNSForm 8.5 (EPT/NON-RI)
17th Mar 20253:06 pmGNWForm 8.3 - Crimson Tide Plc
17th Mar 202512:00 pmRNSForm 8.5 (EPT/RI)
14th Mar 20253:05 pmGNWForm 8.3 - Crimson Tide Plc
14th Mar 202511:58 amRNSForm 8.5 (EPT/RI)
12th Mar 202512:05 pmRNSForm 8.5 (EPT/RI)
12th Mar 20259:23 amRNSForm 8.5 (EPT/NON-RI)
11th Mar 202510:32 amRNSForm 8.5 (EPT/RI)
11th Mar 20257:00 amRNSOffer Update
10th Mar 202512:01 pmRNSForm 8.5 (EPT/RI)
7th Mar 202512:23 pmRNSForm 8.3 - Crimson Tide plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.